Search Clinical Trials in the European Union

>2 years
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
1041-1060 of 1,743 trials

Remyelination in Multiple Sclerosis: PET-MR Study

We are investigating how myelin repair happens in people with multiple sclerosis using advanced imaging techniques. This study aims to understand the role of neuroinflammation in the repair process.

Progressive Relapsing Multiple Sclerosis>2 yearsConfirmation phase (III)Neurology

Vitiligo Treatment: Methotrexate and UVB Phototherapy

We are studying whether combining methotrexate with UVB phototherapy helps adults with progressive vitiligo achieve better skin repigmentation. We will also assess the safety of this treatment and its impact on quality of life.

Vitiligo>2 yearsEfficacy phase (II)Investigational MedicinesDermatology

Head and Neck or Liver Cancer: Testing New Drug Combinations

We are studying whether combinations of BI 765063, ezabenlimab, chemotherapy, cetuximab, and BI 836880 can help people with head and neck or liver cancer. This research aims to find more effective treatment options.

Head and Neck Squamous Cell Carcinoma (HNSCC)Hepatocellular Carcinoma>2 yearsSafety phase (I)Oncology

Advanced Solid Tumors: INCB123667 Study

We are testing a new drug, INCB123667, alone and with other cancer therapies for people with advanced solid tumors. The goal is to understand its effects and potential benefits in treating these cancers.

Advanced Cancer>2 yearsSafety phase (I)Oncology

Squamous Cell Carcinoma of the Penis: Lymphadenectomy and Chemotherapy Study

We are studying a treatment combining surgery and chemotherapy for patients with inguinal lymph node metastases. The goal is to see if this approach improves survival and reduces the chance of cancer returning.

Penis Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Heart Attack Treatment: Cangrelor and Bivalirudin

We are studying a new combination of medications for patients with heart attacks in critical condition. The goal is to see if this treatment can prevent blood clots while keeping bleeding risks low.

Cardiogenic Shock>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesCardiologyInternal Medicine

Anorexia Nervosa: Sertraline Pharmacokinetics Study

We are exploring how a single dose of sertraline is processed in the body of female patients with anorexia nervosa compared to healthy women. This study may help improve treatment approaches for anorexia.

Anorexia Nervosa>2 yearsSafety phase (I)Psychiatry

Lutetium Lu 177 Edotreotide for Pediatric Tumors

We are studying a new targeted therapy for children with somatostatin receptor-positive tumors to find the right dose and evaluate its safety. This trial will also look at how well the treatment works compared to standard care.

RhabdomyosarcomaLymphomaNeuroendocrine Tumor>2 yearsSafety phase (I)No PlaceboInvestigational MedicinesOncologyPediatrics

Diffuse Large B-Cell Lymphoma: Axicabtagene Ciloleucel Study

We are studying a new treatment for patients with late relapse of diffuse large B-cell lymphoma to see if it improves their condition and quality of life. The trial also looks at the safety of this treatment.

Recurrent B-cell Non-Hodgkin's Lymphoma>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesHematologyOncology

Advanced Solid Tumors: RO7567132 and Atezolizumab Study

We are investigating the safety and effectiveness of RO7567132 alone and with Atezolizumab in patients with advanced or metastatic solid tumors. This study aims to learn how the body processes the drug and its potential benefits.

Advanced and Metastatic Solid Tumors>2 yearsSafety phase (I)Oncology

Prostate Cancer Diagnosis: 18F-PSMA PET/MRI Study

We are testing a new imaging method to see how well it identifies clinically significant prostate cancer. This may help improve diagnosis accuracy for patients.

Prostate Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOtolaryngologyUrology

IgG4-Related Disease: Abatacept Treatment Study

We are investigating whether abatacept can help reduce the risk of disease recurrence in people with IgG4-related disease. This study aims to provide insights into a new treatment option for managing this condition.

IgG4-Related Disease>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesInternal MedicineRheumatology

Kidney Health: CO2 Injection in Vascular Procedures

We are testing a new method using Carbon Dioxide instead of traditional contrast media for patients at risk of kidney injury during vascular interventions. This study aims to see if it can help prevent serious kidney problems after the procedure.

Peripheral Arterial Disease (PAD)>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboInvestigational MedicinesPartially RemoteCardiologyNephrology

Shingrix Vaccine: Safety in Psoriasis and Psoriatic Arthritis

We are studying the safety and immune response of the Shingrix vaccine in patients with psoriasis or psoriatic arthritis. Our goal is to see how the vaccine affects disease activity and to monitor any side effects.

Psoriatic ArthritisPsoriasis Vulgaris>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesPartially RemoteAllergologyDermatology

Advanced Cancers with BRAF Mutations: Sorafenib and Trametinib Study

We are testing a combination of two medications for patients with advanced-stage cancers that have BRAF mutations. The goal is to find the best dose and understand how well this treatment works and its safety.

Advanced-Stage Cancer with BRAF Mutation>2 yearsSafety phase (I)Efficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesOncology

Primary Adrenal Insufficiency: Plenadren vs. Cortisone

We are investigating how treatment with Plenadren affects quality of life compared to cortisone in individuals aged 16-80 newly diagnosed with primary adrenal insufficiency.

Primary Adrenal Insufficiency>2 yearsConfirmation phase (III)Monitoring phase (IV)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteEndocrinology

Castration-Resistant Prostate Cancer: CC-1 Antibody Study

We are testing a new bispecific antibody for patients with castration-resistant prostate cancer. The study aims to evaluate its safety and how well it may work compared to existing treatments.

Prostate Cancer>2 yearsSafety phase (I)Efficacy phase (II)OncologyUrology

Cirrhosis Due to NASH/MASH: Efruxifermin Study

We are testing a new medication, Efruxifermin, for people with compensated cirrhosis from NASH/MASH. The study aims to see if it improves liver health and reduces related health risks compared to a placebo.

Non-Alcoholic Steatohepatitis (NASH)Metabolic Dysfunction-Associated Steatohepatitis (MASH)>2 yearsConfirmation phase (III)Investigational MedicinesCost ReimbursementEndocrinologyHepatology

Bladder Cancer: EG-70 Treatment Study

We are testing a new treatment called EG-70 for patients with bladder cancer that hasn't responded to standard therapy. The study aims to see if it can help improve outcomes and quality of life for these patients.

Non-muscle invasive bladder cancer>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesOncologyUrology

Acute Heart Failure: Intra-Abdominal Pressure and Ultrasound Study

We are exploring whether using intra-abdominal pressure and ultrasound can improve diuretic treatment for patients with acute heart failure. This study aims to see if these methods help reduce congestion and improve recovery compared to standard treatment.

Acute Heart Failure>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesCardiologyInternal Medicine